Assetmark Inc. Has $6.18 Million Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Assetmark Inc. raised its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 10.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 69,059 shares of the medical equipment provider's stock after acquiring an additional 6,257 shares during the quarter. Assetmark Inc. owned approximately 0.10% of Lantheus worth $6,178,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LNTH. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus in the third quarter valued at about $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus in the fourth quarter valued at about $27,000. UMB Bank n.a. raised its holdings in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares during the last quarter. RiverPark Advisors LLC bought a new position in shares of Lantheus in the third quarter valued at about $74,000. Finally, Farther Finance Advisors LLC raised its holdings in shares of Lantheus by 226.7% in the third quarter. Farther Finance Advisors LLC now owns 758 shares of the medical equipment provider's stock valued at $83,000 after buying an additional 526 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

Lantheus Price Performance

Shares of Lantheus stock traded up $6.11 during trading on Friday, hitting $106.34. 1,369,851 shares of the company were exchanged, compared to its average volume of 921,738. The firm has a market capitalization of $7.28 billion, a P/E ratio of 17.69 and a beta of 0.38. Lantheus Holdings, Inc. has a 1-year low of $56.44 and a 1-year high of $126.89. The firm's fifty day moving average price is $90.71 and its 200 day moving average price is $96.85.

Remove Ads

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Transactions at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company's stock.

Analyst Ratings Changes

LNTH has been the subject of a number of research analyst reports. StockNews.com cut Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Truist Financial boosted their price objective on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. JMP Securities reissued a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Finally, The Goldman Sachs Group began coverage on Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective for the company. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $132.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.